文献速递免疫规划慢病防控与筛查

澳大利亚HPV疫苗接种10年效果及九价疫苗可预防的额外疾病负担

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
PubMed 文献 · Euro Surveill · 2018-01-01

澳大利亚自2007年起实施四价HPV疫苗国家接种计划,2013年扩展至男孩,接种率全球领先。非系统性文献综述显示,疫苗适龄女性中高级别宫颈病变和生殖器疣显著下降, heterosexual men中也观察到生殖器疣发病率和HPV患病率下降,提示群体效应。九价疫苗预期可预防高达90%的宫颈癌和96%的肛门癌。

要点

  • 四价HPV疫苗显著降低适龄女性高级别宫颈病变和生殖器疣。
  • 男性接种前已见异性恋男性生殖器疣和HPV患病率下降,提示群体效应。
  • 九价疫苗可额外预防187例肛门生殖器癌。

核心结论

  • 四价HPV疫苗对澳大利亚HPV相关疾病产生显著影响,九价疫苗可进一步降低癌症负担。

研究设计与样本

  • 非系统性文献综述,纳入澳大利亚HPV疫苗接种前后HPV相关疾病和感染负担研究及关键国家报告。

主要发现

  • 疫苗适龄女性中高级别宫颈病变和生殖器疣大幅下降。
  • 男性接种计划引入前,同龄异性恋男性生殖器疣发病率和HPV患病率已下降,表明群体效应。
  • 九价HPV疫苗预期可预防高达90%的宫颈癌和96%的肛门癌。
  • 2012年估计1544例HPV相关癌症中,四价疫苗可预防1242例,九价疫苗可额外预防187例肛门生殖器癌。

临床怎么用

  • 维持男女高接种率可实现澳大利亚疫苗型HPV疾病的消除。

局限性

  • 非系统性文献综述,可能未全面覆盖所有相关研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide. AIM: We report on the impact of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine. METHODS: We performed a non-systematic literature review of studies measuring the burden of HPV-associated disease and infection in Australia before and after introduction of HPV vaccination. We also included key national reports with estimates of HPV-related disease burden. RESULTS: Substantial declines in high-grade cervical disease and genital warts among vaccine-eligible women have been observed. Reductions in genital warts incidence and HPV prevalence among heterosexual men of similar age were observed before introduction of the male vaccination programme, indicating a substantial herd effect. 9vHPV vaccine is expected to prevent up to 90% of cervical and 96% of anal cancers. Of an estimated 1,544 HPV-associated cancers in 2012, 1,242 would have been preventable by the 4vHPV vaccine and an additional 187 anogenital cancers by the 9vHPV vaccine. CONCLUSIONS: Vaccination using 4vHPV vaccine has had a large demonstrable impact on HPV-related disease in Australia. A switch to 9vHPV could further reduce the HPV-associated cancer burden. With continued high coverage among both males and females, elimination of vaccine-type HPV disease seems achievable in Australia.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018. PMID: 30326995. doi:10.2807/1560-7917.ES.2018.23.41.1700737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。